CTLA4 and pneumonitis: The risks of pneumonitis related to these agents have not been fully reported and given known risks of pneumonitis with PD-(L)1 and CTLA4 inhibitors, it will be interesting to see if these agents have similar toxicity profiles compared to current standard treatments.